3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Thromboembolism of Vein VTE in Colorectal Cancer
1
Thromboembolism
1
Pulmonary Embolism
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Kidney Neoplasms
1
Fatigue
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Interventions
Dalteparin
11
apixaban
9
Enoxaparin
7
edoxaban
5
Tinzaparin
5
Rivaroxaban
4
Heparin, Low-Molecular-Weight
4
Dabigatran
3
bemiparin
2
abelacimab
2
Warfarin
2
Nadroparin
2
MAA868
2
Fondaparinux
2
reviparin
1
myotubularin
1
isoquercitrin
1
certoparin
1
atezolizumab
1
acarboxyprothrombin
1
Ultrasonography, Doppler, Duplex
1
Rosuvastatin Calcium
1
Phenprocoumon
1
Models, Biological
1
Medication Therapy Management
1
Intermittent Pneumatic Compression Devices
1
Imaging, Three-Dimensional
1
Hospitals
1
Heparin
1
Fluorodeoxyglucose F18
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Venous Thrombosis
×
isoquercitrin
×
Clear all
NCT06861088
2026-02-02
CATIQ P3
Quercis Pharma AG
Phase 3
Recruiting
480 enrolled